Serina Therapeutics Files S-1/A, Reports $1.45M Cash

Ticker: SER · Form: S-1/A · Filed: Jul 3, 2024 · CIK: 1708599

Serina Therapeutics, Inc. S-1/A Filing Summary
FieldDetail
CompanySerina Therapeutics, Inc. (SER)
Form TypeS-1/A
Filed DateJul 3, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001, $13.20, $18.00, $8.8999, $0.01
Sentimentneutral

Sentiment: neutral

Topics: S-1/A, financial-update, amendment

TL;DR

Serina Therapeutics (fka AgeX) filed S-1/A, has $1.45M cash as of 3/31/24. Watch for restatement details.

AI Summary

Serina Therapeutics, Inc. (formerly AgeX Therapeutics, Inc.) filed an S-1/A on July 3, 2024, detailing its financial status. As of March 31, 2024, the company had $1.45 million in cash and cash equivalents. The filing also references restatement adjustments for the fiscal years ending December 31, 2023, and 2022.

Why It Matters

This S-1/A filing provides an update on Serina Therapeutics' financial position, including cash reserves, which is crucial information for investors and stakeholders assessing the company's operational runway and future prospects.

Risk Assessment

Risk Level: medium — The filing indicates restatement adjustments, which can signal accounting complexities or potential issues that warrant further investigation by investors.

Key Numbers

  • $1.45M — Cash and Cash Equivalents (As of March 31, 2024, indicating the company's liquidity.)
  • 20240703 — Filing Date (Indicates the date of the S-1/A amendment.)

Key Players & Entities

  • Serina Therapeutics, Inc. (company) — Filer
  • AgeX Therapeutics, Inc. (company) — Former company name
  • $1.45 million (dollar_amount) — Cash and cash equivalents as of March 31, 2024
  • July 3, 2024 (date) — Filing date
  • December 31, 2023 (date) — Fiscal year end with restatement adjustments
  • December 31, 2022 (date) — Fiscal year end with restatement adjustments

FAQ

What is the primary purpose of this S-1/A filing for Serina Therapeutics, Inc.?

The S-1/A filing serves as an amendment to a previous registration statement, likely to update financial information, disclose material changes, or provide further details relevant to investors.

What was Serina Therapeutics, Inc. previously known as?

Serina Therapeutics, Inc. was formerly known as AgeX Therapeutics, Inc., as indicated by the 'FORMER COMPANY' and 'FORMER CONFORMED NAME' fields.

What were the reported cash and cash equivalents as of March 31, 2024?

The filing indicates that Serina Therapeutics, Inc. had $1.45 million in cash and cash equivalents as of March 31, 2024.

What fiscal years are mentioned in relation to restatement adjustments?

The filing mentions restatement adjustments for the fiscal years ending December 31, 2023, and December 31, 2022.

Where is Serina Therapeutics, Inc. headquartered?

Serina Therapeutics, Inc. is headquartered in Huntsville, Alabama, with its business and mail address listed as 601 Genome Way, Suite 2001, Huntsville, AL 35806.

Filing Stats: 4,532 words · 18 min read · ~15 pages · Grade level 16.5 · Accepted 2024-07-03 17:03:40

Key Financial Figures

  • $0.0001 — d the Company's common stock, par value $0.0001 per share ("common stock"), began tradi
  • $13.20 — ercisable at an exercise price equal to $13.20 per warrant for (i) one share of the Co
  • $18.00 — ercisable at an exercise price equal to $18.00 per warrant for one share of common sto
  • $8.8999 — ted sales price of our common stock was $8.8999 per share. We are an "emerging growth
  • $0.01 — s the shares of common stock, par value $0.01 per share, of Legacy Serina. " Legacy
  • $1.07 billion — we have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fisca
  • $1.0 billion — date on which we have issued more than $1.0 billion in nonconvertible debt securities durin

Filing Documents

BUSINESS

BUSINESS 77 MANAGEMENT 134 EXECUTIVE COMPENSATION 141 RELATED PERSON TRANSACTIONS 149

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 156 LEGAL PROCEEDINGS 158 SELLING SECURITYHOLDERS 159 DESCRIPTION OF SECURITIES 160 PLAN OF DISTRIBUTION 165 CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS 168 LEGAL MATTERS 173 EXPERTS 173 CHANGE IN AUDITOR 173 WHERE YOU CAN FIND MORE INFORMATION 174 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on the information provided in this prospectus, as well as the information incorporated by reference into this prospectus and any applicable prospectus supplement. Neither we nor the selling securityholders have authorized anyone to provide you with different information. Neither we nor the selling securityholders are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus, any applicable prospectus supplement or any documents incorporated by reference is accurate as of any date other than the date of the applicable document. Since the date of this prospectus and the documents incorporated by reference into this prospectus, our business, financial condition, results of operations and prospects may have changed. i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC") using the "shelf" registration process. Under this shelf registration process, the selling securityholders may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such selling securityholders of the securities offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of common stock issuable upon the exercise of any Warrants. We will receive proceeds from any exercise of the Warrants for cash. Neither we nor the selling securityholders have authorized anyone to p

View Full Filing

View this S-1/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.